ANIP ANI Pharmaceuticals, Inc.
Stock · NasdaqGM · United States · Healthcare · US00182C1036
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by ANI Pharmaceuticals, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price
67.41 USD
-3.17%
52-week range
67.14 – 90.87
Dividend yield—
Market cap1.5B
NowoTrade score
82 Grade A
Price history
Daily prices in USD.
Updated 08 Nov 2026 14:54. Information, not advice.
Results
Next results
26 Feb 2027
in 110 days · 08:00 · estimate 2.82
Last results
2.70 vs 2.18 estimated
05 Nov 2026 · Beat +23.8%
Beat the estimate
12 of 12
0 missed · 0 in line · 12 beats in a row
Average surprise
+21.3%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 26 Feb 2027 08:00 | 2.82 | — | — | Upcoming |
| 05 Nov 2026 06:00 | 2.18 | 2.70 | +23.8% | Beat |
| 07 Aug 2026 06:00 | 2.04 | 2.21 | +8.2% | Beat |
| 08 May 2026 06:00 | 1.30 | 2.05 | +57.8% | Beat |
| 27 Feb 2026 06:00 | 1.98 | 2.33 | +17.9% | Beat |
| 07 Nov 2025 06:00 | 1.77 | 2.04 | +15.3% | Beat |
| 08 Aug 2025 06:00 | 1.42 | 1.80 | +26.8% | Beat |
| 09 May 2025 06:00 | 1.38 | 1.70 | +23.0% | Beat |
| 28 Feb 2025 06:00 | 1.44 | 1.63 | +13.6% | Beat |
| 08 Nov 2024 06:00 | 1.09 | 1.34 | +23.4% | Beat |
| 06 Aug 2024 06:00 | 0.95 | 1.02 | +7.4% | Beat |
| 10 May 2024 07:00 | 1.00 | 1.21 | +21.5% | Beat |
| 29 Feb 2024 06:00 | 0.86 | 1.00 | +17.0% | Beat |
| 08 Nov 2023 07:00 | 0.84 | 1.27 | +50.6% | Beat |
| 09 Aug 2023 06:00 | 0.67 | 1.28 | +92.0% | Beat |
| 08 May 2023 06:00 | 0.35 | 1.17 | +232.4% | Beat |
| 09 Mar 2023 06:00 | 0.67 | 0.76 | +13.1% | Beat |
| 09 Nov 2022 06:00 | 0.55 | 0.64 | +15.8% | Beat |
| 08 Aug 2022 06:00 | 0.22 | 0.13 | -40.9% | Miss |
| 10 May 2022 06:00 | 0.09 | -0.12 | -228.6% | Miss |
| 15 Mar 2022 06:00 | 0.74 | 0.52 | -29.2% | Miss |
| 01 Nov 2021 08:00 | 0.70 | 1.01 | +44.3% | Beat |
| 06 Aug 2021 08:00 | 0.61 | 0.67 | +10.7% | Beat |
| 07 May 2021 06:00 | 0.71 | 1.04 | +46.5% | Beat |
| 09 Mar 2021 06:00 | 0.94 | 0.80 | -15.2% | Miss |
| 05 Nov 2020 08:00 | 0.88 | 0.97 | +9.8% | Beat |
| 06 Aug 2020 06:00 | 0.75 | 0.69 | -7.6% | Miss |
| 07 May 2020 08:00 | 0.89 | 1.04 | +16.9% | Beat |
| 27 Feb 2020 08:00 | 1.18 | 1.08 | -8.7% | Miss |
| 06 Nov 2019 08:00 | 1.43 | 1.23 | -14.0% | Miss |
| 07 Aug 2019 08:00 | 1.29 | 1.44 | +12.1% | Beat |
| 09 May 2019 08:00 | 1.05 | 1.30 | +24.2% | Beat |
| 27 Feb 2019 08:00 | 1.24 | 1.32 | +6.5% | Beat |
| 06 Nov 2018 08:00 | 1.17 | 1.29 | +10.3% | Beat |
| 07 Aug 2018 08:00 | 1.34 | 1.13 | -15.7% | Miss |
| 08 May 2018 08:00 | 1.27 | 1.32 | +3.5% | Beat |
| 27 Feb 2018 08:00 | 1.05 | 1.08 | +3.4% | Beat |
| 02 Nov 2017 08:00 | 0.99 | 1.11 | +12.1% | Beat |
| 03 Aug 2017 08:00 | 0.86 | 0.98 | +14.0% | Beat |
| 04 May 2017 08:00 | 0.79 | 0.74 | -6.3% | Miss |
| 02 Mar 2017 08:00 | 1.10 | 0.90 | -18.2% | Miss |
| 03 Nov 2016 08:00 | 1.08 | 1.09 | +1.2% | Beat |
| 04 Aug 2016 08:00 | 0.77 | 1.11 | +44.2% | Beat |
| 05 May 2016 08:00 | 0.70 | 0.76 | +8.6% | Beat |
| 23 Feb 2016 08:00 | 0.57 | 0.52 | -9.6% | Miss |
| 03 Nov 2015 08:00 | 0.55 | 0.63 | +14.0% | Beat |
| 04 Aug 2015 08:00 | 0.55 | 0.55 | 0.0% | In line |
| 05 May 2015 08:00 | 0.53 | 0.57 | +7.6% | Beat |
| 19 Feb 2015 08:00 | 0.56 | 0.67 | +19.6% | Beat |
| 03 Nov 2014 08:00 | 0.46 | 0.66 | +45.1% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 883.4M | +43.8% | 78.3M | 8.9% | 3.32 | +419.2% | 150.9M |
| 2024 | 614.4M | +26.2% | -18.5M | -3.0% | -1.04 | -222.4% | 47.1M |
| 2023 | 486.8M | +53.9% | 18.8M | 3.9% | 0.85 | +127.9% | 100.4M |
| 2022 | 316.4M | — | -47.9M | -15.1% | -3.05 | — | -47.7M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 18 Dec 2023 – 22 Dec 2023 | 52.88 | 53.76 | 51.88 | 53.43 | +0.98% | 893,900 | |
| 11 Dec 2023 – 15 Dec 2023 | 49.21 | 53.99 | 48.56 | 52.91 | +8.11% | 1,280,500 | |
| 04 Dec 2023 – 08 Dec 2023 | 50.41 | 51.50 | 48.20 | 48.94 | -3.22% | 810,100 | |
| 27 Nov 2023 – 01 Dec 2023 | 51.66 | 52.27 | 49.20 | 50.57 | -2.47% | 824,600 | |
| 20 Nov 2023 – 24 Nov 2023 | 51.36 | 53.50 | 50.77 | 51.85 | +0.90% | 563,300 | |
| 13 Nov 2023 – 17 Nov 2023 | 52.03 | 54.29 | 50.57 | 51.39 | -1.48% | 879,000 | |
| 06 Nov 2023 – 10 Nov 2023 | 65.82 | 65.82 | 51.09 | 52.16 | -20.28% | 1,732,600 | |
| 30 Oct 2023 – 03 Nov 2023 | 59.52 | 65.50 | 58.73 | 65.43 | +11.12% | 630,400 | |
| 23 Oct 2023 – 27 Oct 2023 | 57.11 | 61.59 | 56.53 | 58.88 | +2.51% | 755,500 | |
| 16 Oct 2023 – 20 Oct 2023 | 57.75 | 59.59 | 56.50 | 57.44 | -0.38% | 676,900 | |
| 09 Oct 2023 – 13 Oct 2023 | 58.53 | 60.67 | 57.20 | 57.66 | -1.25% | 763,000 | |
| 02 Oct 2023 – 06 Oct 2023 | 57.66 | 59.49 | 55.55 | 58.39 | +0.57% | 611,400 | |
| 25 Sep 2023 – 29 Sep 2023 | 58.71 | 60.67 | 57.54 | 58.06 | -0.79% | 540,900 | |
| 18 Sep 2023 – 22 Sep 2023 | 62.23 | 62.99 | 58.35 | 58.52 | -6.20% | 589,200 | |
| 11 Sep 2023 – 15 Sep 2023 | 62.06 | 65.18 | 61.45 | 62.39 | +0.73% | 1,369,000 | |
| 05 Sep 2023 – 08 Sep 2023 | 64.57 | 64.84 | 61.32 | 61.94 | -4.09% | 607,500 | |
| 28 Aug 2023 – 01 Sep 2023 | 64.26 | 65.89 | 62.50 | 64.58 | +1.21% | 1,246,500 | |
| 21 Aug 2023 – 25 Aug 2023 | 58.90 | 64.56 | 58.90 | 63.81 | +6.90% | 1,187,300 | |
| 14 Aug 2023 – 18 Aug 2023 | 62.58 | 62.61 | 58.35 | 59.69 | -4.72% | 1,446,000 | |
| 07 Aug 2023 – 11 Aug 2023 | 53.57 | 63.10 | 52.79 | 62.65 | +16.51% | 996,200 | |
| 31 Jul 2023 – 04 Aug 2023 | 52.59 | 53.83 | 50.13 | 53.77 | +2.69% | 408,200 | |
| 24 Jul 2023 – 28 Jul 2023 | 52.41 | 53.60 | 51.27 | 52.36 | +0.33% | 320,900 | |
| 17 Jul 2023 – 21 Jul 2023 | 50.35 | 53.50 | 49.77 | 52.19 | +3.80% | 402,800 | |
| 10 Jul 2023 – 14 Jul 2023 | 52.01 | 52.19 | 49.98 | 50.28 | -3.36% | 448,700 | |
| 03 Jul 2023 – 07 Jul 2023 | 53.52 | 54.37 | 51.98 | 52.03 | -3.34% | 363,200 |
Page 7 of 11
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Is ANI Pharmaceuticals (ANIP) A Bargain After Its $560m Deal? (opens in a new tab) Simply Wall St. · 08 Nov 2026 10:13
- ANI Pharmaceuticals (ANIP) Offers $560 Million For Rare Disease Expansion (opens in a new tab) Simply Wall St. · 08 Nov 2026 09:12
- Should ANI Pharmaceuticals (ANIP) Look Undervalued As Results Land And Revenue Guidance Narrows? (opens in a new tab) Simply Wall St. · 08 Nov 2026 08:09
- ANI Pharmaceuticals, Inc. (ANIP) Q3 2026 Earnings Call Transcript (opens in a new tab) SeekingAlpha · 07 Nov 2026 09:44
- Guggenheim Maintains Buy on ANI Pharmaceuticals, Raises Price Target to $121 (opens in a new tab) Benzinga · 06 Nov 2026 12:12
- ANI Pharmaceuticals Inc (ANIP) Q3 2026 Earnings Call Highlights: Strong Revenue Growth Offset ... (opens in a new tab) GuruFocus.com · 06 Nov 2026 01:17
- ANI Pharma (ANIP) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 05 Nov 2026 20:09
- ANI Pharmaceuticals Q3 Earnings Call Highlights (opens in a new tab) MarketBeat · 05 Nov 2026 18:15
- ANI (ANIP) Reports Q3 Earnings: What Key Metrics Have to Say (opens in a new tab) Zacks · 05 Nov 2026 13:30
- ANI Pharmaceuticals (NASDAQ:ANIP) reports strong Q3 2026 (opens in a new tab) StockStory · 05 Nov 2026 12:40
- ANI Pharmaceuticals (ANIP) Surpasses Q3 Earnings and Revenue Estimates (opens in a new tab) Zacks · 05 Nov 2026 12:15
- ANI: Q3 Earnings Snapshot (opens in a new tab) Associated Press · 05 Nov 2026 11:59
- ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results (opens in a new tab) 05 Nov 2026 11:51
- REPEAT – ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business (opens in a new tab) 05 Nov 2026 11:50
- ANI Pharmaceuticals Q3 2026 Earnings Call Transcript (opens in a new tab) Benzinga · 05 Nov 2026 10:46
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 69.62 USD
- Market cap
- 1.5B
- Exchange
- NasdaqGM
- Country
- United States
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 25.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 14.0 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 15.9 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 15.0 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A).
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (trailing) | 13.4× | Good | 30.65× |
| P/E (forward) | 6.66× | Good | 14.89× |
| Price / book | 2.26× | Fair | 3.8× |
| Price / sales | 1.47× | Good | 3.19× |
| EV / EBITDA | 6.83× | Good | 12.61× |
| Free cash flow yield | 12% | Good | 2.5% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 61.1% | Good | 58.6% |
| Operating margin | 17.8% | Good | 7.6% |
| Net margin | 11.2% | Good | 2.7% |
| Return on equity | 20.4% | Good | 5.7% |
| Return on assets | 6.4% | Fair | 3.5% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 40.8% | Good | 10.8% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.97× | Fair | 0.48× |
| Net debt / EBITDA | 0.77× | Good | 1.6× |
| Interest cover | 4.05× | Fair | 2.65× |
| Current ratio | 2.75× | Good | 2.36× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
| Payout of free cash flow | 0.6% | Good | 28.8% |
| Payout of free cash flow (3 years) | 1.5% | Good | — |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow ANIP and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.